Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Improved cost‐effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia AOriginal Research · 1997 · 117 citations
2Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspectiveRCT · 2003 · 102 citations
3Issues complicating precision dosing for factor VIII prophylaxisOriginal Research · 2018 · 11 citations
4Pharmacokinetic–Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate2024
5Association of peak factor <scp>VIII</scp> levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxisOriginal Research · 2016 · 67 citations
6Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia ACost-Effectiveness Analysis · 2016 · 24 citations
7Personalized prophylaxis in people with hemophilia A: challenges and achievementsCost-Effectiveness Analysis · 2016 · 19 citations
8Physiologically Based Pharmacokinetic (PBPK) Modeling of FIX in Pediatric Hemophilia B: Extravascular Distribution and Dosing OptimizationOriginal Research · 2026
9Perinatal outcomes of direct oral anticoagulant exposure during pregnancy: An analysis of the French pharmacovigilance databaseResearch and Practice in Thrombosis and Haemostasis · 2026
10Antithrombotic Strategies for Thrombosis Treatment and Thromboprophylaxis in Pediatric Cardiac Disease: A 20-Year Systematic Review of Prospective Studies and Clinical TrialsResearch and Practice in Thrombosis and Haemostasis · 2026

More from Research and Practice in Thrombosis and Haemostasis

More from University of Amsterdam